Press release, Research news // 10th June 2019
Press release, Research news // 10th June 2019
Myeloma UK is launching a new research programme to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme (UKMRA-Myeloma UK-CARP).
This initiative is part of an ambitious new strategy Myeloma UK recently published with a mission to make myeloma history. One of our key approaches to achieve this was through investment in myeloma research.
The UKMRA-Myeloma UK-CARP is an evolution of the Myeloma UK Clinical Trials Network (CTN) which was launched in 2009 and resulted in the delivery of nine early phase clinical trials, and over 700 patients taking part. It will build on the successes of the CTN to support and catalyse the development of early phase myeloma clinical trials in the UK. Through this initiative, UK myeloma patients will be able to access new treatments or treatment combinations as part of trials.
Strategically, UKMRA-Myeloma UK-CARP will support the development of studies which either provide a proof of concept data for larger and later phase trials, or data which can be used to support patients gaining access to treatments through the NHS. Included in the programme will be an exploration of ‘adaptive trials’, an innovation which allows researchers to learn from patient responses to treatment during the trial and gives them flexibility to adapt the treatment accordingly.
This new collaborative model will combine the patient insight from Myeloma UK with the experience and expertise of the UK Myeloma UK Research Alliance and the University of Leeds Clinical Trials Research Unit (CTRU) to develop a portfolio of early phase clinical trials. The investment from Myeloma UK will help catalyse trial development and facilitate funding from external sources such as pharmaceutical companies and diagnostics companies to support the delivery of innovative trials developed through the UKMRA-Myeloma UK-CARP.
The funding is also an investment in myeloma clinical trial infrastructure. The Initiative will help support the further development of myeloma research capacity in the UK and keep the UK at the forefront of myeloma research. It also provides an opportunity for early career researchers or clinicians seeking trials experience to get advice and develop their skills with the expertise and support of the UKMRA and the University of Leeds CTRU.
UKMRA-Myeloma UK-CARP is the only initiative in the UK focused on the development of early phase trials to meet the needs of myeloma patients. The programme focuses on designing trials and answering the questions which matter most to UK myeloma patients, carers and myeloma specialists.
The UK Myeloma Research Alliance is a clinical research cooperative with the aim of coordinating and aligning UK trial strategy and delivery. Professor Gordon Cook, Chair of the UKMRA said
“Building on what has already been achieved through the Myeloma UK Clinical Trials Network we can develop a strong portfolio of early-phase trials through UKMRA-Myeloma UK-CARP and crucially, link these directly to the development of late-phase trials through the UKMRA to change clinical practice and patient outcomes”
Dr Sarah Brown from the University of Leeds Clinical Trials Research Unit (CTRU) commented:
“The launch of the UKMRA-Myeloma UK-CARP shows the commitment of Myeloma UK, the UKMRA and the University of Leeds CTRU to advance myeloma research in the UK and builds upon the strong relationships and successes of the Myeloma UK Clinical Trials Network over the last 10 years”
Dr Jayne Galinsky, Health Services Research Manager at Myeloma UK says:
“From a health service research perspective, we are pleased to launch a research programme which is not only designed generate the best results for patients but also fully incorporates patients and carers throughout trial design.”
Dr Simon Ridley, Director of Research at Myeloma UK says:
“We are pleased to be supporting an innovative partnership with the UKMRA and with the Leeds CTRU to support a robust clinical trial research programme for myeloma running in the UK. Not only does it help give UK myeloma patients access to innovative treatments but also ensures that the right research is taking place to support approval of improved treatments .”
A: Yes. Our goal is to make myeloma history. One of our key strategies to do this is by finding answers through the investment in myeloma research. Myeloma UK is still investing in clinical trials. The UK Myeloma Research Alliance-Myeloma UK–Concept and Access Research Programme (UKMRA-Myeloma UK-CARP) is a three year grant to support and facilitate the development of new clinical trials for myeloma patients.
UKMRA-Myeloma UK–CARP is a new initiative designed to catalyse the development of myeloma patient centric, early phase (Phase 1 or 2) clinical trials. Through this initiative Myeloma UK will collaborate with the UK Myeloma Research Alliance (UKMRA) and the University of Leeds Clinical Trials Research Unit (CTRU) to develop early phase clinical trials to meet the needs of myeloma patients. The initiative will focus on trials, which will provide proof of concept data for larger Phase 3 trials or generate additional data to support patients gaining access to treatments through the NHS.
The UK Myeloma Research Alliance is a clinical research cooperative of leading UK myeloma experts. It was set-up to develop a collaborative and unified UK trial strategy to deliver truly impactful clinical research that facilitates change in clinical practice within the UK and beyond.
A: UKMRA-Myeloma UK–CARP is an evolution of the Myeloma UK Clinical Trials Network (CTN). Like the Myeloma UK CTN the UKMRA-Myeloma UK–CARP will support early phase myeloma trials designed to answer the questions which matter to UK myeloma patients, and myeloma specialists. The initiative will also utilise the strong relationships built as part of the CTN to set-up clinical trials at research sites across the UK so myeloma patients across the country have the potential to access novel therapies through clinical trials. The main difference is the funding model. UKMRA-Myeloma UK–CARP, will use a more sustainable, long-term funding model. Myeloma UK will provide funds to support and accelerate the development of the early phase trials, which will be delivered through further funding from external sources such as pharmaceutical and diagnostics companies. This investment helps to support oversight of the early phase trials portfolio, helping researchers develop trial ideas and secure funding.
It is hoped this model will help develop more trials, more quickly. This investment from Myeloma UK will help accelerate trial set-up by ensuring early funding is available to support the development of new trial ideas. It is anticipated that more developed trial concepts will be more attractive investments for companies developing new myeloma treatments. We hope this will catalyse the development of more clinical trials in the UK and giving more myeloma patients across the UK the opportunity to access new treatments through clinical trials.
A: All parties have worked hard to ensure on-going MUK clinical trials will not be impacted. Patients currently receiving treatment through a Myeloma UK clinical trial will continue to receive treatments. All on-going trials will continue until considered complete.
Researchers do not need to be a member of the UKMRA to benefit from UKMRA-Myeloma UK-CARP funding. Any researcher with a proposal for an early phase, patient centric myeloma trials can approach University of Leeds CTRU to enquire about support for their trial. To find out more, please contact University of Leeds CTRU